Chlorpromazine versus penfluridol for schizophrenia

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Chlorpromazine is a benchmark antipsychotic, but its efficacy compared to other agents like penfluridol is not fully established.
• Penfluridol, an older antipsychotic, has a long half-life, potentially offering dosing advantages.

Purpose of the Study:

• To compare the clinical effects of chlorpromazine versus penfluridol in adults diagnosed with schizophrenia.

Main Methods:

• A systematic search of trial registries and databases was conducted without limitations on date, language, or publication status.
• Three randomized clinical trials involving 130 participants were included, analyzing outcomes such as hospital admissions, mental state, and adverse effects.

Main Results:

• No significant differences were observed between chlorpromazine and penfluridol regarding hospital admissions or akathisia incidence.
• Participants in both groups had similar rates of early study withdrawal; chlorpromazine was associated with a lower risk of requiring antiparkinsonian medication.
• Low-quality evidence from three small studies indicates similar efficacy and adverse effect profiles, with no reported deaths or usable data on global/mental state changes.

Conclusions:

• Limited data suggest comparable efficacy and side effect profiles between chlorpromazine and penfluridol for schizophrenia treatment.
• Penfluridol's long half-life may present a practical advantage in administration frequency.
• High-quality randomized clinical trials are necessary to draw definitive conclusions and justify the use of these antipsychotics.